Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1622 1626 1627
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258903 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | Final Rejection | Merck Sharp & Dohme LLC |
| 17995806 | PI3 KINASE INHIBITORS AND USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 17623060 | COMPOSITIONS AND METHODS OF TREATING LIVER CANCERS | Final Rejection | The Johns Hopkins University |
| 17996550 | 2-(HET)ARYL-SUBSTITUTED CONDENSED HETEROCYCLIC DERIVATIVES AS PEST CONTROL AGENTS | Non-Final OA | Bayer Aktiengesellschaft |
| 18262053 | ARTEMISININ-PROTEASOME INHIBITOR CONJUGATES AND THEIR USE IN THE TREATMENT OF DISEASE | Non-Final OA | CORNELL UNIVERSITY |
| 17997594 | CD73 COMPOUNDS | Final Rejection | Gilead Sciences, Inc. |
| 18286944 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | Non-Final OA | Neurocrine Biosciences, Inc. |
| 18533622 | METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17999185 | MEK-INHIBITORS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | Final Rejection | ATRIVA THERAPEUTICS GMBH |
| 17867294 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Final Rejection | Celgene Corporation |
| 18570244 | INHIBITOR COMPOUNDS | Non-Final OA | NeoPhore Limited |
| 18534576 | USE OF COLCHICINE TO INHIBIT TUMOR GROWTH AND METASTASES | Non-Final OA | Murray and Poole Enterprises, LTD. |
| 18289805 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Non-Final OA | Evopoint Biosciences Co., Ltd. |
| 18256153 | PHARMACEUTICAL COMPOSITION | Final Rejection | FUJIFILM TOYAMA CHEMICAL CO., LTD. |
| 17769416 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | Final Rejection | IMPACT THERAPEUTICS (SHANGHAI), INC |
| 18255262 | LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | Final Rejection | METRIOPHARM AG |
| 18250402 | CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION | Non-Final OA | MINERALYS THERAPEUTICS, INC. |
| 17917729 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Final Rejection | REMIX THERAPEUTICS INC. |
| 17614826 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
| 17920703 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | Final Rejection | NAGASAKI UNIVERSITY |
| 17639401 | METHODS OF TREATING EPILEPSY USING THE SAME | Non-Final OA | Trevena, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy